Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · March 31, 2017

Results Up to 4 Years From the OSLER-1 Extension Study on Evolocumab for Hypercholesterolemia

JAMA Cardiology

 

Additional Info

JAMA Cardiology
Long-Term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
JAMA Cardiol 2017 Mar 14;[EPub Ahead of Print], MJ Koren, MS Sabatine, RP Giugliano, G Langslet, SD Wiviott, H Kassahun, A Ruzza, Y Ma, R Somaratne, FJ Raal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading